Relevant Use of Factor Xa inhibitor in Patients with Non-Valvular Atrial Fibrillation (RESPIRE trial): a multicenter, prospective, non- interventional, observational study

Korea University Anam Hospital0 个研究点目标入组 2,000 人开始时间: 待定最近更新: 2022年11月28日

试验速览

暂无简介。

•1)Males and females over 19 years old
•2)Patients diagnosed with NVAF
•3)Patients with CHA2DS2-VASc score of 1 (2 for females)
•* CHA2DS2-VASc score: Assess the risk of stroke up to 9 points by considering the following factors: Congestive heart failure (+1 point), Hypertension (+1 point), Age 75 or over (+2 points), Diabetes mellitus (+1 point), Stroke (+2 points), Transient Ischemic Attack (TIA)/Thromboembolism (TE), Vascular disease (+1 point each), Age 65-74 (+1 point), and Sex (+1 point for females).[6]
•4)When the investigator determines that the use of an anticoagulant is necessary to prevent stroke or systemic embolism
•5)Patients who have no history of taking medications containing Apixaban within 6 months of screening
•6)When the patients who understand the description of this study, agree to participate in the study, and completed/submitted the informed consent form

•1)Patients who are contraindicated according to the precautions for using Apixaban
•2)Pregnant and lactating women

发起方